All right. Thanks very much. Happy to be here with the Seaport Therapeutics team. We'll do Q&A and keep it conversational, but maybe I'll start off by throwing it over to Lauren White, CFO, to kick it off, give a quick overview of Seaport, maybe talk about the next data events coming up in 2027 and 2028, and then we'll dive into it.
Sure. Sounds good.
Awesome. Thank you.
Big thank you, Paul, for having us here today, and a warm welcome to those in the audience and on the webcast. We are going to be sharing some forward-looking statements today, which are based on our expectations and beliefs, and we encourage you to look at our SEC filings. I'd like to start by taking a step back and just looking bigger picture at the opportunity. There's over 1 billion people living globally with mental illness. Over 300 million suffer from depression, and over 300 million suffer from anxiety. There's hardly a family that's not touched. When you look at the existing treatments that are out there, they're successes. They're deemed commercially viable, they generate billions of dollars in sales, and more importantly, they help millions of patients, but they all have limitations that have held them back.
Seaport Therapeutics is a neuropsychiatry company that is focused on turning the tide of mental health and focusing on bringing new therapies to patients. We are a clinically validated platform. We have got a robust pipeline of three programs that we will talk about today, and we have got an experienced team that is really focused on how we execute our trials. Our lead program, GlyphAllo, is currently in a phase II-B potential registration-enabling study in MDD. Our second program, GlyphAgo, we recently shared key proof-of-concept data, and we just dosed our patient in a phase II-A trial in generalized anxiety disorder. Our third program, Glyph2BLSD, is in preclinical development. While still early, given all of the excitement in the psychedelic space, the key thesis there is, can you get the benefit of a psychedelic without the trip?
We at Seaport are focused on programs that are clinically validated, meaning they have generated human efficacy, but they were held back by some sort of a limitation that we are able to address with our Glyph platform. Glyph is a lymphatic targeting prodrug platform that is able to overcome issues such as poor oral bioavailability, liver-related AEs, and other side effects. The great thing is that every time we Glyph a molecule, we generate new composition of matter IP. We have got a seasoned leadership team with a track record of success, both in bringing new medicines to patients and in delivering on successful business outcomes. You are probably aware that our CEO, Daphne Zohar, and our board chair, Steve Paul, founded and led Karuna. We are actually taking a similar approach at Seaport that Karuna took.
For example, at Karuna, they knew that xanomeline worked, but it was sitting on a shelf due to GI tolerability issues. The team was able to overcome those issues with the invention of KarXT, now called COBENFY. Looking ahead, we believe our cash runway is $403 million, and that will take us into 2029, which is what we have currently guided to, and we get through three really exciting clinical readouts. We get through our top-line readout of our current trial in GlyphAllo, BUOY-1. That is in the first half of 2027. Then we move into our second program, GlyphAgo. We get our phase II-A readout in early 2028, and our phase II/III potentially registration-enabling trial at the end of 2028. Paul, we are really looking forward to the path ahead over the next few years.
Great. Thanks, Lauren. Appreciate it. Maybe starting with GlyphAllo, I lived through every moment of Sage from IPO to the acquisition, and the program in MDD definitely had some super high ups and some downs as well. I guess, how do you guys make sense of the totality of the data there, and your confidence that that is not just a PPD drug, it is really an MDD mechanism too?
I wonder if we can start by just saying a few words about the Glyph platform and bring a little bit more detail to that. Michael, do you want to just go us that, expand on that a bit?
Sure. With the Glyph technology, which as Lauren mentioned, is a lymphatic targeted technology, we are able to change the PK profile of drugs like allopregnanolone, very relevant to the experience that Sage had with the original IV product, ZULRESSO, which clearly had efficacy in postpartum depression and had some advantages that Tony will speak on. Overall, Glyph is a technology platform based on dietary fat, so it allows us to cloak a molecule as if it were a fat, which changes the way that it's absorbed by the body, allowing us to bypass first-pass metabolism at the level of the liver. This is important for allowing drugs, for example, allopregnanolone, that were only previously available as an IV form to be delivered orally. For example, in clinical trials, we've shown that GlyphAllo is able to achieve comparable exposures as that IV allopregnanolone, but with once-daily oral dosing.
As Lauren mentioned, we also recently announced top-line data showing clinical validation for our second program, GlyphAgo, which again validates an aspect of the Glyph technology. I think this is all relevant as we look back towards the Sage experience into having a differentiated program with GlyphAllo, not only in the molecule, but also how we design and execute clinical trials to show that molecule's potential efficacy.
Okay. So yeah, maybe going back to the zuranolone data.
Yeah. I think Michael sort of hit some of the high points there. GlyphAllo or Glyph allopregnanolone is a neuroactive steroid that's an endogenous or naturally occurring compound, that has, based on Sage and other relevant third-party trials, antidepressant, anti-anxiety, and sleep-promoting effects, that already are well-established and therefore de-risk the molecule in terms of our own use of it in clinical development. Sage did bring allopregnanolone to the clinic in the form of IV brexanolone, and that's important because it reflects the fact, as Michael noted, that allopregnanolone by itself is not orally bioavailable. In fact, about 90%-95% of it is chewed up by the liver if administered orally, and there just isn't sufficient PK, sufficient exposure to have therapeutic effects at the level of the brain after straight oral ingestion.
The 60-hour continuous IV infusion of IV allopregnanolone, on the other hand, was very effective in the treatment of patients, women with postpartum depression. You saw this rapid onset of effect consistently across their trials, and you saw that there was substantial improvement that was durable and lasted after the infusion ended, all the way through several weeks, up to about four weeks post-infusion. Sage also brought forward zuranolone, which is a synthetic analog of allopregnanolone, in an attempt to enhance the oral bioavailability of the neurosteroid mechanism, and succeeded at extending the half-life of zuranolone and also creating a once-daily orally bioavailable agent. That was very helpful, and it was introduced into MDD studies.
The good news is that most of those studies, five out of six of those trials, as you know, Paul, succeeded in hitting the primary endpoint, which is at two weeks of treatment exposure in people with MDD. So, very good track record of that molecule in terms of major depressive disorder and major depressive episode. The problem is, and the bad news was, that the drug did not hit at six weeks, which was the minimum that FDA really expected for a drug in MDD to show at least some appropriate sustained or durable effects at around six to eight weeks.
The point being that Sage did not treat patients beyond two weeks, and therefore, arguably, it was a bit unsurprising if you have patients off treatment for a month before assessing them at the week six endpoint, albeit a secondary endpoint, there's not going to be a lot of separation. That is one of the major lessons learned from that zuranolone program. We think that the problem with zuranolone is not so much the biology or the pharmacology of the drug, but clinical design aspects and construction. We've clearly incorporated those lessons into our Seaport development program for GlyphAllo, Glyph allopregnanolone, and in the currently ongoing MDD trial, patients with major depressive episode, we are treating for a full six weeks, once daily, at night, at bedtime, and we'll be assessing at six weeks using the HAMD-17 endpoint.
There is also an open-label extension for an additional six weeks daily dose beyond that. The other aspect to the Sage zuranolone trials that I think hampered their outcome, perhaps even at six weeks, is that there was a clear amplification of placebo response that was larger than what one would normally expect to see in trials in MDD, important though placebo effects are in this therapeutic area. In tracing that back, we undertook a significant examination of their trials, as well as all MDD trials done by industry in the last 10 years in the form of a meta-analysis that's been presented at some scientific conferences recently. A number of variables that you might think could be associated with placebo response actually were not.
One thing stuck out, which was the frequency of clinician-administered assessments, or CAAs, the frequency that patients were coming into the clinic to be assessed and the number and frequencies of those assessments in the course of the trials that they were participating in. The Sage trials had a high volume of those, about two or even higher than 2x greater than what is commonly seen in these trials. I think this is something that we've also learned and internalized and incorporated into our study. We've optimized the number of CAAs and reduced them to the maximum extent possible. I think there's a lot of potential for allopregnanolone. We've seen that based on these previous data and third-party data, and we're very hopeful for the outcome of the current study.
You guys are partially enriching your study for patients with comorbid anxiety. Can you talk about why you're doing that and what that offers you and what that sort of implies for the different sort of scenarios for success in this trial?
There's a number of unmet needs that we're hoping to address and working hard to address in the context of the GlyphAllo MDD development program, one of which is the fact that there's a high prevalence of comorbid anxiety symptoms in people with major depressive episode. DSM-5 has formally recognized this and specified it as a specifier known as anxious distress. We have included patients explicitly diagnosed as having both MDD as the background diagnosis and underlying psychiatric condition together with anxious distress. These are people who have persistent anxiety, feelings of impending doom, poor concentration, worry, feelings of loss of bodily control that occur on most days or the majority of days of the current major depressive episode. This is a major unmet need.
Speaking as a psychiatrist myself, these are patients who often show reduced responses to current or existing pharmacotherapy, more treatment resistance, more functional impairment, worse longer-term outcomes, and more suicidality, more substance and alcohol use as well. This is a somewhat difficult to treat group, but it occurs in 60%-70%, depending on the study, of patients with MDD. We have pre-specified this subgroup as being of interest in our currently ongoing study. We have stratified on this subgroup, on this variable, and we will be carefully looking at it.
The idea being that based on the pharmacology of GlyphAllo and allopregnanolone, and based on the results of previous work done by Sage and others involving neurosteroids and looking at the potential for anti-anxiety effects, which makes sense given the mechanism involved at GABA-A receptors, we think that this could be a very interesting differentiation for GlyphAllo and an interesting patient population for us to study further as we move forward.
Is that the kind of thing where you might, if the study does not work overall but looks good in that subgroup, could you advance development for that population specifically?
Depending on the outcome of the study, to be clear, the primary analysis for the currently ongoing MDD study, which is a global, multi-regional placebo-controlled trial, is all comers. We are looking at all subjects, up to a total of 360 subjects. But depending on how qualitatively we assess effects on patients with anxious distress versus non-anxious distress patients, to your point, Paul, and seeing whether or not there is a selective advantage or benefit for patients for anxious distress, that is a group that we think we might focus on moving forward. But that is subject to further discussion, results of the study, and discussion with FDA.
Yep. Okay. There are two elements of GlyphAllo itself that I wanted to ask about. The first is the half-life being shorter than zuranolone. Maybe talk about your confidence why a shorter PK half-life wouldn't imply some sort of efficacy disadvantage. Then I think the second piece on the positive side is your confidence in your ability to dose longer than two weeks or dose chronically. Zuranolone was tripped up there as well. Maybe just can you help differentiate those two nuances?
Yeah. I'm happy to talk about the half-life, and it's relevant not only from an efficacy perspective, but more so I would say from a safety perspective. To that point, I think it's important to acknowledge that zuranolone, despite its effectiveness, comes with a warning label around driving. That's a 12-hour driving restriction. That's in part due to, as Tony mentioned, the extended half-life of zuranolone. The modifications done to increase bioavailability carry that lingering PK effect where you still have relatively high blood levels 8, 10, 12 hours post-dose. As a result, when zuranolone conducted a driving simulation study, a next-day driving simulation study, there was a separation from placebo. That is, it showed a next-day driving impairment.
We've recently conducted and announced top-line data from a driving impairment study showing that GlyphAllo has no next-day driving impairment, either after a single dose or after a repeated dose, in a very standard and similar study design as was used by zuranolone. This really comes down to your point, Paul, the PK differences, where with GlyphAllo, by six to eight hours post-dose, you're at 15% or less of the actual Cmax levels. So your blood levels of allopregnanolone have diminished. But to the point on efficacy, the important point is not necessarily hitting some trough level of PK across 24 hours, but consistent dosing over time. In fact, we have examples in neuropsychiatry of drugs with extremely short half-lives that nonetheless, when dosed daily chronically, actually result in strong efficacy.
One very pertinent example for Seaport is actually agomelatine, which has a half-life on the order of one to two hours, but yet has clear efficacy in both major depression as well as generalized anxiety disorder. Now, there are other limitations of that particular drug we can get into, but I think it's a great example of that disconnect between the sort of acute PK/PD and what you need to see for efficacy.
Yep. Okay. Then maybe on your ability to dose chronically, can you talk about the degree to which you've de-risked that at this point?
Yeah, I think a few things to note here. One is, as this has been discussed, Sage really dosed zuranolone for two weeks, and it seemed that it's really a choice to dose for two weeks as a regimen, as a paradigm. We are dosing in BUOY-1 for six weeks in the main study period, as well as six weeks in the open-label extension. So already, outpatient in an ongoing study, we've shown the ability to dose chronically, and that's our intent for the therapy going forward.
Yep. Okay. Makes sense. Anything else you want to add on this upcoming readout? What else can you sort of say about the overall bar for success for Seaport?
I think not only do you need an active drug with a mechanism that is de-risked and that has the potential for well-differentiated clinical efficacy, and I think we have that with GlyphAllo. You have to be able to execute these trials, design and execute them in ways that truly allow this kind of clinical benefit to show themselves and be demonstrated. To that end, we've assembled an experienced team at Seaport and have thought very carefully about these study design aspects and elements. I've already addressed something about the clinical assessments and the frequency with which those are administered. Other design elements that I think are important for the MDD trial, as well as more generally for others that we're embarking on, is the way in which you randomize patients, the number of active arms in a study versus the placebo arm.
For example, in the GlyphAllo study, we have one active and one placebo arm, so one-to-one randomization. It's tempting to sort of build in a lot of arms and a lot of doses and try to look at dose response in a study, but if you do too much of those bells and whistles, you can get into trouble because the patients involved in the study can perceive and have the expectation that they're going to be more likely to be on, quote, "active treatment" than placebo with, say, two or three active arms, than a study such as the current one, which is 50% chance of being on placebo, significant chance. I think that is a way of reducing this expectancy bias and the placebo response that goes along with that. Flexible dosing is something that we've built into the current study as well.
We're starting at the lowest dose level and then moving up through a total of three doses, three dose levels to the max dose in a way that matches the needs of the patient, both in terms of efficacy and tolerability, to the pharmacology and the profile of the drug. You can optimize treatment with a flexible dose paradigm in a way that's more difficult with fixed dose. I think we've already addressed, for example, the anxious distress subgroup, and that's a kind of way of, if you will, enriching for drug response and limiting placebo response because those patients tend not to do so well on placebo, and we think that that's also an area that will help us as we move forward with the study.
I think with everything that Tony mentioned, that really leads to the bar for us for BUOY-1 to be a statistically significant separation between drug and placebo. But to the broader capabilities of allopregnanolone and therefore GlyphAllo, we'll also be looking at clinical benefit in domains like the rapidity of action, as we saw with IV ZULRESSO and zuranolone, as well as the potential benefit, as Tony mentioned, in anxious distress, as well as sleep. That's a huge area of unmet need in depression because SSRIs make sleep worse. Of course, SSRIs also have side effect profile, sexual dysfunction, weight gain, that we feel GlyphAllo could also differentiate on in BUOY-1.
Yep. Okay, great. Maybe switching gears to GlyphAgo, we don't have a ton of time, so let's briefly just talk about the thesis there, old agomelatine data and anxiety, why that product wasn't brought to the U.S., and what GlyphAgo offers.
Yeah, I think agomelatine matches this pattern of validated clinical pharmacology. Agomelatine is an approved drug outside of the U.S., so in Europe and Australia. It works clearly in MDD and in GAD, especially where there have been four placebo-controlled trials where agomelatine statistically significantly separates from placebo in all four studies. As a melatonin receptor agonist and serotonin 2C receptor antagonist, it doesn't have the baggage of SSRIs, SNRIs, benzodiazepines. It's well-tolerated, it's efficacious, but it's a little bit rough on the liver. A small portion of patients will have liver enzyme increases, and so on label, you need liver function monitoring, blood tests before initiating treatment, several weeks during treatment, as well as every time you increase the dose. This has really blunted the commercial and clinical potential of agomelatine.
The hypothesis here is that liver enzyme increases due to that first-pass effect, how much drug is hitting the liver. But we know the exposures that lead to efficacy with agomelatine, so we've created GlyphAgo, which, as with all Glyph products, are new composition of matter drugs. For GlyphAgo, the idea is to increase the bioavailability and therefore get to the exposure that we know is efficacious with agomelatine, but reduce the amount of drug that the liver sees. Liver sees less drug, liver's less stressed out, and we can reduce or eliminate the liver enzyme elevations and the testing requirement. We've put out now phase I top-line data showing that we can do exactly that for GlyphAgo.
Number one, we can increase the bioavailability by about 6.8-fold relative to agomelatine, whereas an increase of about two-fold is what we've calculated as needing to skirt that liver enzyme issue. Number two, we've also reduced the PK variability of agomelatine by about 10-fold. Agomelatine has very variable PK, as one would expect from a high first-pass metabolism drug. That can mean some patients who are randomized to agomelatine get very little agomelatine circulating. We don't see that with GlyphAgo. We see a far more consistent PK profile. Finally, agomelatine has issues like drug-drug interactions that can affect the PK, for example, with common drugs like some types of oral contraceptives. We do not see that with GlyphAgo, again, because that drug-drug interaction is happening in the liver, the exact thing that we are bypassing with Glyph via GlyphAgo.
We were excited in the past week or two to actually start a phase II-A proof of pharmacology study for GlyphAgo in patients with GAD and sleep dysfunction. We're also gearing up a phase II/III potential registration-enabling study of GlyphAgo in generalized anxiety disorder, which, to zoom out, huge unmet need. The last approved drug was about 20 years ago for GAD.
Yep. Okay. Very interesting. Thank you. As it relates to your phase II-A, maybe talk about the design and goals of that study. I guess if those data are positive, what would be the caveats to read through onto the II-B? Like, how different is the population?
Yeah, so it is GAD. In the phase II-A, we are focusing on GAD with sleep disturbance.
Is that like in a specific enriched population? Okay.
Yeah, and it's of course a major subset. Just as anxious distress is a major subset, as you would expect, sleep is a huge issue in anxiety as well as in depression. This study's a little different than the II-B, or the phase II/III rather, in that it is focused on sleep. So a lot of the endpoints will be focused on sleep. It has a few more bells and whistles so that we can carefully characterize sleep using multiple doses of GlyphAgo, which would provide a lot of information about the benefits of GlyphAgo, the potential benefits on sleep, something that's actually been seen already with agomelatine, and therefore we could expect to see with GlyphAgo. But we want to Tony's earlier points, try to keep some of that intensive intervention and monitoring outside of our registration-enabling phase II/III that we'll be booting up.
We really want that later study to be a clean potential registration-enabling study. They provide, in our view, complementary pieces of information.
Yep. Okay. As it relates to anxiety drug development, there has been a lot less activity here than there has been in MDD. Is it the same principles of patient selection and placebo effect mitigation that come into play in these types of trials?
I think so, very much so overlapping. If anything, in anxiety disorders, including GAD, we see larger placebo effects. So it is even more crucial. I think that at Seaport, this is a consideration that we have top of mind constantly and speak to our internal teams and our external partners virtually on a daily basis about. We are very careful and thoughtful about scrutinizing every aspect of the study in order to show that we can minimize placebo, the noise, if you will, that is introduced in a study, and maximize the signal and the output of the active drug group. So we start with very careful selection of sites. We look at countries globally. We look at sites within those countries, the most experienced investigators with the best track records based on our own experience and expertise, and based on that of others.
We use a variety of methods, including partners who can help us ensure that we maintain the highest quality of participant or patient screening and enrollment throughout the course of the study. One very key point to minimization of noise and/or placebo effects is ensuring that raters accurately assess patients, both in terms of diagnosis at the initiation of the study and in terms of the severities and the scales, the severity assessments such as the HAMD or the HAMA at baseline and throughout the study. This is much easier said than done.
It's much harder to do than you would think, because it takes great skill to be able to interview a patient with psychiatric disease, a very subjective sort of set of symptoms that the patient has to reveal to you over time and that you have to elicit in careful and thoughtful ways, utilizing the structured scales that we use. We audiotape all of these assessments, diagnostic and scale assessments over time, involving our expert partners, and we listen to those, and we provide feedback and remediation to these raters at the various sites across the globe where the studies are being conducted, as needed, to ensure that they're keeping faithfully to the conventions of the scale, guidelines of the assessments, and ensuring consistency within sites and across sites throughout the trial. This is a huge effort.
We oversee each and every patient coming into the study, randomized subject in this way, and it's true whether you do MDD or GAD. We plan to sort of continue this theme, this track record, as we move forward in both mood and anxiety disorders.
Okay, great. We're about a minute over time. I know we could talk for like another half hour, but maybe just to wrap things up, Lauren, do you want to talk about cash runway?
Yeah, sure. We ended Q3 with just north of $403 million on our balance sheet. That provides us runway into 2029, and as mentioned earlier, we covered three upcoming key clinical readouts. We are really excited about our catalysts looking ahead.
Okay, great. Thanks. Best of luck. Appreciate it.
Thank you, Paul.
Thank you.